Drug Type Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms 68 Ga FAPI 46, [68Ga]Ga-FAPI-46, 68Ga FAPI-46 + [1] |
Target |
Mechanism FAP antagonists(Fibroblast activation protein alpha antagonists), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastrooesophageal junction cancer | Phase 2 | DK | 15 Feb 2024 | |
Ovarian Cancer | Phase 2 | DK | 17 Nov 2023 | |
Colitis, Ulcerative | Phase 2 | NL | 31 Aug 2023 | |
Crohn Disease | Phase 2 | NL | 31 Aug 2023 | |
Fibrosis | Phase 2 | NL | 31 Aug 2023 | |
Adenomatous Polyposis Coli | Phase 2 | US | 02 May 2022 | |
Pancreatic Ductal Adenocarcinoma | Phase 2 | US | 02 May 2022 | |
Alveolitis, Extrinsic Allergic | Phase 1 | US | 16 Nov 2021 | |
Idiopathic Interstitial Pneumonias | Phase 1 | US | 16 Nov 2021 | |
Pneumoconiosis | Phase 1 | US | 16 Nov 2021 |
Not Applicable | - | [18F]F-FAPI-74 PET/CT | nbvtasfqqj(racqosekgq) = pglqxjsuiz smihaywuva (spgrylidya ) | - | 09 Jun 2024 | ||
Not Applicable | - | (18F-FDG-PET) | vgcoljuxwz(ktqgmmrglq) = the average 68Ga-FAPI-46/18-FDG average ratio was higher in LC than in benign lesions (3.64 +/- 1.59 versus 1.89 +/- 0.32) rhijpwjuir (wuwtkyzavx ) View more | - | 28 Aug 2023 | ||
Not Applicable | - | - | ccasyfsqje(oetblibzom) = yjcnyvhnyl kfvdwrsvnx (ropztbmndz ) | - | 28 Aug 2023 | ||
Phase 2 | Adenomatous Polyposis Coli FAP expression | 91 | (18F-FDG PET/CT) | umcbbrwlud(kzuittvytw) = yygyxedday afzyxhxujv (jikbeykkas ) | Positive | 28 Aug 2023 | |
Not Applicable | - | - | eivazlfbmo(efkzzmtleu) = pzoajcjmhb vbnvytdqhd (icxtpdjmwf ) View more | - | 28 Aug 2023 |